Diagnosed with VHL Disease or Kidney Tumors? What Welireg’s Targeted Approach Changes
Introduction
Being diagnosed with von Hippel-Lindau (VHL) disease can feel overwhelming. Because VHL can cause tumors to develop in different parts of the body over time,1,2 many people wonder what treatment options are available and whether surgery is always necessary. Today, targeted medicines such as Welireg provide an additional treatment option for some adults with VHL disease whose tumors require treatment but do not need immediate surgery.3
What is VHL Disease?
VHL disease is an inherited condition passed down through families. It is caused by a change (mutation) in the VHL gene, which normally helps prevent abnormal cell growth. Because of this change, people with VHL have a higher chance of developing tumors or cysts in different organs throughout their lives.4
How VHL Disease Can Lead to Kidney, Brain, Spinal, and Pancreatic Tumors
The VHL gene normally helps control how cells respond to oxygen. When this gene does not work properly, certain proteins stay switched on for longer than they should. This can encourage tumors to grow in organs such as the kidneys, brain, spinal cord and pancreas.1
Why Some VHL-Related Tumors Need Treatment but Not Immediate Surgery
In some cases, doctors may recommend regular monitoring instead of immediate surgery, radiation, or other procedures. While these treatments can remove or control individual tumors, they do not prevent new tumors from developing. Because VHL is a lifelong condition, treatment may also focus on controlling tumors throughout the body.5 This is where targeted medicines such as Welireg may play a role for some patients.
What is Welireg?
Welireg is the brand name for belzutifan, an oral medicine approved by the United States Food and Drug Administration for adults with VHL disease who need treatment for renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that do not require immediate surgery. Because it works throughout the body, Welireg may help treat tumors in more than one organ, which matters in a disease where multiple tumors can appear over time.4
How Welireg Works as a Targeted Treatment
Welireg works by blocking a protein called HIF-2 alpha, which plays an important role in helping VHL-related tumors grow. By targeting this protein, Welireg helps slow tumor growth and can shrink some tumors. Because it works throughout the body, it may help treat VHL-associated tumors in different organs, including the kidneys, pancreas, brain, and spinal cord.6,7
Welireg and Kidney Tumors: What Patients Should Know
One of the goals of treating VHL-related kidney tumors is to preserve kidney function while reducing the need for repeated surgeries. Welireg may help shrink some kidney tumors and slow their growth, which may help delay or reduce the need for additional procedures in some patients.2 However, it is not a replacement for surgery in every case, and your healthcare team will recommend the most appropriate treatment for your condition.
What to Expect During Treatment Monitoring
Welireg can cause anemia and hypoxia, so monitoring is essential before and during treatment. Hemoglobin should be checked for anemia before starting therapy and periodically during treatment, and oxygen saturation should also be monitored because severe hypoxia may require treatment interruption, supplemental oxygen, or hospitalization.6,8
Questions to Ask Before Starting Welireg
Starting a new treatment can feel overwhelming. Asking these questions can help you understand what to expect before and during treatment.
- Does the tumor need treatment now, or can it continue to be monitored?
- Is Welireg the right treatment option for this type of tumor?
- What benefits can be expected from treatment with Welireg?
- How often will blood tests and oxygen levels be checked during treatment?
- Which side effects should be reported immediately?
- Could the Welireg dose need to be interrupted, reduced, or stopped if side effects occur?
How Rx4u May Support Access Through Named Patient Program Guidance
WELIREG is not yet routinely available in the Indian pharmaceutical market. However, eligible patients may be able to access this medicine through the Named Patient Program (NPP).9
This program allows patients to legally import medicines approved in other countries but not yet launched in India, under medical supervision and regulatory approval.
Step-by-Step: How to Access WELIREG in India via NPP
1. Consultation With a Specialist
Consult an oncologist or another specialist experienced in managing VHL disease. The healthcare team will determine whether WELIREG is an appropriate treatment option based on the patient's condition.
2. Medical Documentation
If WELIREG is considered appropriate, the treating doctor will provide a prescription and a medical justification explaining why the medicine is needed
3. Supporting Medical Records
Relevant medical documents, such as imaging reports, pathology reports, genetic testing (if applicable), and treatment history, may be required to support the request.
4. Regulatory Approval
An application is submitted to the appropriate regulatory authorities to obtain permission for importing WELIREG under the Named Patient Program.
5. Assistance With the Access Process
Authorized service providers, such as Rx4U India, may assist with documentation, coordination of the import process, and delivery of the medicine after the necessary approvals have been obtained.
Conclusion: Understanding Targeted Treatment Options in VHL Disease
Welireg offers a targeted treatment option for some adults with VHL disease whose tumors require treatment but do not need immediate surgery. By helping control tumors in different parts of the body, it may reduce the need for repeated procedures in some patients. The doctor will determine whether Welireg is the right treatment option.2,6,8
Medical Disclaimer:
This information is provided for educational purposes only and is not a substitute for professional medical advice. Medicine should only be taken under the guidance of a qualified healthcare provider. Patients should always consult their doctor for advice on diagnosis, treatment, and medication use, and should not make changes to their prescribed therapy without medical supervision.
References
- Larcher A, Belladelli F, Fallara G, et al. Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians. Asian J Urol. 2022;9(4):430-442. doi: 10.1016/j.ajur.2022.08.002.
- Srinivasan R, Iliopoulos O, Beckermann KE, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025;26(5):571-582. doi:10.1016/S1470-2045(25)00099-3.
- EMA. Published February 27, 2025. Updated January 13, 2026. Accessed July 21, 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/welireg.
- Aronow ME, Wiley HE, Gaudric A, et al. Von Hippel-Lindau disease: Update on pathogenesis and systemic aspects. Retina. 2019;39(12):2243-2253. doi:10.1097/IAE.0000000000002555.
- European Medicines Agency. First medicine to treat rare genetic disorder causing cysts and tumours. December 13, 2024. Accessed July 16, 2026. https://www.ema.europa.eu/en/news/first-medicine-treat-rare-genetic-disorder-causing-cysts-tumours.
- US Food and Drug Administration. WELIREG (belzutifan) tablets, for oral use: prescribing information. FDA; August 2021. Accessed July 16, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf
- National Cancer Institute. Belzutifan works steadily in people with VHL-associated tumors. Published June 21, 2024. Accessed July 16, 2026. https://ccr.cancer.gov/news/article/belzutifan-works-steadily-in-people-with-vhl-associated-tumors.
- Fallah J, Brave MH, Weinstock C, et al. FDA approval summary: belzutifan for von Hippel-Lindau disease-associated tumors. Clin Cancer Res. 2022;28(22):4843-4848. doi:10.1158/1078-0432.CCR-22-1054.
- Patil S. Early access programs: Benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016;7(1):4-8. doi:10.4103/2229-3485.173779.
